{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:27:41Z","timestamp":1786595261613,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"First-class discipline innovation-driven talentprogram of Guangxi Medical University"},{"name":"This study was supported by The Guangxi Key Research and Development Project","award":["No. AB24010149"],"award-info":[{"award-number":["No. AB24010149"]}]},{"name":"The Guangxi Clinical Research Center for Enhanced Recovery after Surgery, Guangxi Science and Technology Base and Talent Project","award":["No.AD19245196"],"award-info":[{"award-number":["No.AD19245196"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00856-7","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:14:17Z","timestamp":1780744457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive multi-omics pan-cancer analysis revealed that ANTXR1 is a potential biomarker for diagnosis and immunotherapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Yue","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"856_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"856_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12951-024-03005-2","volume":"22","author":"Y Feng","year":"2024","unstructured":"Feng Y, Tang Q, Wang B, Yang Q, Zhang Y, Lei L, et al. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J Nanobiotechnol. 2024;22:737.","journal-title":"J Nanobiotechnol"},{"key":"856_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-bioeng-110320-110749","volume":"24","author":"W Du","year":"2022","unstructured":"Du W, Nair P, Johnston A, Wu PH, Wirtz D. Cell Trafficking at the Intersection of the Tumor-Immune Compartments. Annu Rev Biomed Eng. 2022;24:275\u2013305.","journal-title":"Annu Rev Biomed Eng"},{"key":"856_CR4","doi-asserted-by":"crossref","unstructured":"Cao Y. Cancer-triggered systemic disease and therapeutic targets. Holist Integr Oncol. 2024;3.","DOI":"10.1007\/s44178-024-00077-w"},{"key":"856_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","volume":"32","author":"Z Cao","year":"2025","unstructured":"Cao Z, Quazi S, Arora S, Osellame LD, Burvenich IJ, Janes PW, et al. Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects. J Biomed Sci. 2025;32:7.","journal-title":"J Biomed Sci"},{"key":"856_CR6","doi-asserted-by":"publisher","first-page":"6808","DOI":"10.7150\/ijbs.119301","volume":"21","author":"DL Boaru","year":"2025","unstructured":"Boaru DL, De Leon-Oliva D, De Castro-Martinez P, Garcia-Montero C, Fraile-Martinez O, Garcia-Gonzalez B, et al. Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies. Int J Biol Sci. 2025;21:6808\u201381.","journal-title":"Int J Biol Sci"},{"key":"856_CR7","first-page":"1197","volume":"289","author":"BS Croix","year":"2000","unstructured":"Croix BS, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes Expressed Hum Tumor Endothelium Sci. 2000;289:1197\u2013202.","journal-title":"Genes Expressed Hum Tumor Endothelium Sci"},{"key":"856_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ccr.2012.01.004","volume":"21","author":"A Chaudhary","year":"2012","unstructured":"Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, et al. TEM8\/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell. 2012;21:212\u201326.","journal-title":"Cancer Cell"},{"key":"856_CR9","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-13-1080","volume":"73","author":"D Chen","year":"2013","unstructured":"Chen D, Bhat-Nakshatri P, Goswami C, Badve S, Nakshatri H. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res. 2013;73:5821\u201333.","journal-title":"Cancer Res"},{"key":"856_CR10","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41467-024-45595-3","volume":"15","author":"M Licaj","year":"2024","unstructured":"Licaj M, Mhaidly R, Kieffer Y, Croizer H, Bonneau C, Meng A, et al. Residual ANTXR1\u2009+\u2009myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway. Nat Commun. 2024;15:1312.","journal-title":"Nat Commun"},{"key":"856_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","volume":"78","author":"TT Byrd","year":"2018","unstructured":"Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, et al. TEM8\/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018;78:489\u2013500.","journal-title":"Cancer Res"},{"key":"856_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/cas.14326","volume":"111","author":"C Cai","year":"2020","unstructured":"Cai C, Dang W, Liu S, Huang L, Li Y, Li G, et al. Anthrax toxin receptor 1\/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K\/AKT\/mTOR signaling pathway. Cancer Sci. 2020;111:1132\u201345.","journal-title":"Cancer Sci"},{"key":"856_CR13","doi-asserted-by":"publisher","first-page":"217917","DOI":"10.1016\/j.canlet.2025.217917","volume":"631","author":"J He","year":"2025","unstructured":"He J, Li W, Wang S, Lan J, Hong X, Liao L, et al. Cancer associated fibroblasts-derived lactate induces oxaliplatin treatment resistance by promoting cancer stemness via ANTXR1 lactylation in colorectal cancer. Cancer Lett. 2025;631:217917.","journal-title":"Cancer Lett"},{"key":"856_CR14","doi-asserted-by":"crossref","unstructured":"Gong Q, Deng J, Zhang L, Zhou C, Fu C, Wang X, et al. Targeted silencing of TEM8 suppresses non\u2013small cell lung cancer tumor growth via the ERK\/Bcl\u20132 signaling pathway. Mol Med Rep. 2021;24.","DOI":"10.3892\/mmr.2021.12234"},{"key":"856_CR15","doi-asserted-by":"publisher","first-page":"598221","DOI":"10.3389\/fmolb.2020.598221","volume":"7","author":"X Huang","year":"2020","unstructured":"Huang X, Zhang J, Zheng Y. ANTXR1 Is a Prognostic Biomarker and Correlates With Stromal and Immune Cell Infiltration in Gastric Cancer. Front Mol Biosci. 2020;7:598221.","journal-title":"Front Mol Biosci"},{"key":"856_CR16","doi-asserted-by":"crossref","unstructured":"Kaminski MF, Bendzick L, Hopps R, Kauffman M, Kodal B, Soignier Y, et al. TEM8 Tri-specific killer engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2022-004725"},{"key":"856_CR17","doi-asserted-by":"publisher","first-page":"E10934","DOI":"10.1073\/pnas.1810664115","volume":"115","author":"N Jayawardena","year":"2018","unstructured":"Jayawardena N, Burga LN, Easingwood RA, Takizawa Y, Wolf M, Bostina M. Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus. Proc Natl Acad Sci U S A. 2018;115:E10934\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"856_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41587-020-0550-z","volume":"38","author":"HH Caicedo","year":"2020","unstructured":"Caicedo HH, Hashimoto DA, Caicedo JC, Pentland A, Pisano GP. Overcoming barriers to early disease intervention. Nat Biotechnol. 2020;38:669\u201373.","journal-title":"Nat Biotechnol"},{"key":"856_CR19","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49:D1420\u201330.","journal-title":"Nucleic Acids Res"},{"key":"856_CR20","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.celrep.2019.04.052","volume":"27","author":"P Zhang","year":"2019","unstructured":"Zhang P, Yang M, Zhang Y, Xiao S, Lai X, Tan A, et al. Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer. Cell Rep. 2019;27:1934\u2013e475.","journal-title":"Cell Rep"},{"key":"856_CR21","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1158\/1078-0432.CCR-21-0792","volume":"27","author":"HY Jeong","year":"2021","unstructured":"Jeong HY, Ham IH, Lee SH, Ryu D, Son SY, Han SU, et al. Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers. Clin Cancer Res. 2021;27:6529\u201342.","journal-title":"Clin Cancer Res"},{"key":"856_CR22","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"856_CR23","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1002\/imt2.238","volume":"3","author":"D Chen","year":"2024","unstructured":"Chen D, Xu L, Xing H, Shen W, Song Z, Li H, et al. Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform. Imeta. 2024;3:e238.","journal-title":"Imeta"},{"key":"856_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"856_CR25","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","volume":"47","author":"H Yuan","year":"2019","unstructured":"Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47:D900\u201308.","journal-title":"Nucleic Acids Res"},{"key":"856_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18\u201327.","journal-title":"Neoplasia"},{"key":"856_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/cas.15244","volume":"113","author":"Y Juntaro","year":"2022","unstructured":"Juntaro Y, Yuki H, Yuji O, Kentaro S, Yoshiyuki S, Kenta M, et al. MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer. Cancer Sci. 2022;113:916\u201325.","journal-title":"Cancer Sci"},{"key":"856_CR28","doi-asserted-by":"publisher","first-page":"D1053","DOI":"10.1093\/nar\/gkad933","volume":"52","author":"Z Xu","year":"2024","unstructured":"Xu Z, Wang W, Yang T, Li L, Ma X, Chen J, et al. STOmicsDB: a comprehensive database for spatial transcriptomics data sharing, analysis and visualization. Nucleic Acids Res. 2024;52:D1053\u201361.","journal-title":"Nucleic Acids Res"},{"key":"856_CR29","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:D956\u201363.","journal-title":"Nucleic Acids Res"},{"key":"856_CR30","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638\u201346.","journal-title":"Nucleic Acids Res"},{"key":"856_CR31","doi-asserted-by":"publisher","first-page":"1113378","DOI":"10.3389\/fphar.2023.1113378","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, Fei Y, Wang H, Hu S, Liu C, Hu R, et al. CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy? Front Pharmacol. 2023;14:1113378.","journal-title":"Front Pharmacol"},{"key":"856_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10:268.","journal-title":"Signal Transduct Target Ther"},{"key":"856_CR33","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00262-019-02392-y","volume":"68","author":"M Sotoudeh","year":"2019","unstructured":"Sotoudeh M, Shakeri R, Dawsey SM, Sharififard B, Ahmadbeigi N, Naderi M. ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy. Cancer Immunol Immunother. 2019;68:1597\u2013603.","journal-title":"Cancer Immunol Immunother"},{"key":"856_CR34","doi-asserted-by":"publisher","first-page":"1520223","DOI":"10.3389\/fmolb.2024.1520223","volume":"11","author":"LS Franco","year":"2024","unstructured":"Franco LS, Arunachalam S, Chauhan A, Kareff SA, Hallenbeck PL. Elevated expression of ANTXR1 gene in tumors is a poor prognostic biomarker for patients with bladder cancer. Front Mol Biosci. 2024;11:1520223.","journal-title":"Front Mol Biosci"},{"key":"856_CR35","doi-asserted-by":"publisher","first-page":"712371","DOI":"10.3389\/fonc.2021.712371","volume":"11","author":"C Ding","year":"2021","unstructured":"Ding C, Liu J, Zhang J, Wan Y, Hu L, Charwudzi A, et al. Tumor Endothelial Marker 8 Promotes Proliferation and Metastasis via the Wnt\/beta-Catenin Signaling Pathway in Lung Adenocarcinoma. Front Oncol. 2021;11:712371.","journal-title":"Front Oncol"},{"key":"856_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-025-02167-1","volume":"10","author":"J Ren","year":"2025","unstructured":"Ren J, Yan G, Yang L, Kong L, Guan Y, Sun H, et al. Cancer chemoprevention: signaling pathways and strategic approaches. Signal Transduct Target Ther. 2025;10:113.","journal-title":"Signal Transduct Target Ther"},{"key":"856_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40164-024-00474-x","volume":"13","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Zong H, Zhu P, Su C, Tang W, Chen Z, et al. Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs. Exp Hematol Oncol. 2024;13:6.","journal-title":"Exp Hematol Oncol"},{"key":"856_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee H, Kim B, Park J, Park S, Yoo G, Yum S, et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther. 2025;10:248.","journal-title":"Signal Transduct Target Ther"},{"key":"856_CR39","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.2147\/CMAR.S298165","volume":"13","author":"L Pietrzyk","year":"2021","unstructured":"Pietrzyk L, Korolczuk A, Matysek M, Arciszewski MB, Torres K. Clinical Value of Detecting Tumor Endothelial Marker 8 (ANTXR1) as a Biomarker in the Diagnosis and Prognosis of Colorectal Cancer. Cancer Manag Res. 2021;13:3113\u201322.","journal-title":"Cancer Manag Res"},{"key":"856_CR40","doi-asserted-by":"crossref","unstructured":"Mehra S, Deshpande N, Nagathihalli N. Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13174434"},{"key":"856_CR41","doi-asserted-by":"publisher","first-page":"e2413457","DOI":"10.1002\/advs.202413457","volume":"12","author":"K Ravi","year":"2025","unstructured":"Ravi K, Zhang Y, Sakala L, Manoharan TJM, Pockaj B, LaBaer J, et al. Tumor Microenvironment On-A-Chip and Single-Cell Analysis Reveal Synergistic Stromal-Immune Crosstalk on Breast Cancer Progression. Adv Sci (Weinh). 2025;12:e2413457.","journal-title":"Adv Sci (Weinh)"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00856-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:42:55Z","timestamp":1786592575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00856-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00856-7","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental procedures were conducted under approval of the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (Approval No. 2026-E0011) and in accordance with the approved study protocol, institutional regulations, and relevant national guidelines. All animal experiments were performed in compliance with the approved protocol. The maximal permitted tumour size was 2.0\u00a0cm in diameter or \u2264\u200910% of body weight, as specified in the ethical approval. Animals were monitored regularly, humane endpoints were applied when required, and the approved tumour burden was not exceeded. Source data for tumour growth analyses are available in accordance with journal data availability requirements. Clinical samples were obtained from the institutional biobank of the First Affiliated Hospital of Guangxi Medical University. All samples were fully de-identified prior to use and were included as part of an approved secondary research protocol. The requirement for informed consent was waived by the Ethics Committee due to the use of anonymized archived specimens. All procedures involving human materials were conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"144"}}